First patient in India receives NervAlign Nerve Cuff
Released
Released
Announcement PDF
+61 (03) 9482 3940
157 Heidelberg Rd,
Northcote, VIC 3070
www.renerve.com.au
ASX Announcement
17 November 2026
First patient in India receives ReNerve’s NervAlign® Nerve Cuff
Highlights
• First patient in India treated with the NervAlign® Nerve Cuff, converting the Company’s CDSCO marketing
approval2
into clinical use
• India is a major market opportunity for ReNerve as the world’s most populous country, with approximately
1.45 billion people and a high incidence of road-trauma related peripheral nerve injuries2
• Achieved with ReNerve’s Indian commercialisation partner, NetCentrix Ventures1
, after receiving India’s
first marketing approval for the Company2
• Follows record September 2026 quarter sales of $584,000, up 176% on the June quarter and exceeding
ReNerve’s full-year FY26 sales, with September the Company’s first month above $200,0003
• Adds to a growing Asia-Pacific footprint, following first cases in Hong Kong and Malaysia6
and marketing
approval in Indonesia5
ReNerve Limited (ASX: RNV, “ReNerve” or “the Company”), an Australian medical device company developing
innovative products for peripheral nerve injury (PNI) repair, is pleased to announce that the first patient in India
has received its FDA-cleared NervAlign® Nerve Cuff, marking the transition from regulatory approval to commercial
use in one of the world’s largest healthcare markets.
The procedure was performed in Bangalore for an upper extremity nerve repair. The case is the first commercial
use of the NervAlign® Nerve Cuff in India and follows the Central Drugs Standard Control Organisation (CDSCO)
marketing approval announced on 10 August 2026, ReNerve’s first product approval in the country2.
The NervAlign® Nerve Cuff is a bioabsorbable protective wrap designed to support and protect nerves during
healing following peripheral nerve injury or surgical repair. The post-operative feedback is very positive from both
surgeon and patient, with the patient recovering well with no post-operative issues.
ReNerve entered its partnership with NetCentrix Ventures in April 2025 to secure regulatory approval for, and
commercialise, the NervAlign® Nerve Cuff in India1
. With CDSCO approval achieved, the partners are now
progressing a coordinated commercialisation strategy tailored to the Indian healthcare system2
.
NetCentrix provides local regulatory expertise and established distribution networks and has commenced surgeon
education and product in-servicing across India. ReNerve is providing clinical and technical support, training and
regulatory liaison, with further cases scheduled over the coming weeks.
India’s population of approximately 1.45 billion, combined with a high incidence of road-trauma related nerve
injuries, underpins a large and growing addressable patient base. The Indian nerve repair market has been
estimated at approximately US$700 million2.
2 | P a g e
ReNerve CEO Dr Julian Chick said:
“The first nerve repair case in India with the NervAlign® Nerve Cuff is a significant moment for ReNerve.
Regulatory approval opened the door in August, and this case shows our partnership with NetCentrix is
turning that approval into surgeons using the product in the operating theatre.
“India has the largest population in the world and a high incidence of trauma (road, industrial, agricultural)
related nerve injuries, which means a very large number of patients who may benefit from better nerve
repair options.
“This milestone builds on our strongest quarter to date, with September quarter sales of $584,000 already
ahead of the whole of FY26. With a growing US business, new Empliq® revenue and now first cases across
Hong Kong, Malaysia and India, we have multiple engines driving growth.”
ReNerve expects to provide further updates as case volumes build in India, and as the Company progresses
commercial entry into Indonesia and the Philippines5. The Company continues to advance the NervAlign® Nerve
Guide Matrix through Stage 3 of its four-stage development program, targeting completion by the end of calendar
2026, and the NervAlign® Nerve Conduit through commercial scale-up ahead of market launch3,4.
The first Indian case comes as ReNerve’s sales continue to accelerate. During the September 2026 quarter the
Company:
• Delivered record quarterly sales of $584,000, up 176% on the June 2026 quarter ($211,000) and 774% on
the corresponding quarter last year3
;
• Achieved quarterly sales exceeding the Company’s full-year FY26 result ($510,357), with September its
first month of sales above $200,0003
; and
• Continued to build its US distribution network, which stood at 21 partners at the end of FY26, alongside
purchasing approvals across the US Department of Defence and Veterans Affairs healthcare systems and
growing uptake of the Empliq® human tissue range4
.
In Asia-Pacific, the Company has now progressed from regulatory approval to clinical use in Hong Kong, Malaysia
and India2,6, and holds marketing approval in Indonesia5. ReNerve now has commercial activity across the United
States, New Zealand, Hong Kong, Thailand, Malaysia, Indonesia, the Philippines and, with this first case, India4
.
ENDS -
This announcement has been approved for release by the Company’s Board of Directors.
References
The following ASX announcements by ReNerve Limited are referred to in this release and are available at www.asx.com.au (ASX:RNV):
1. ReNerve Expands Global Footprint with Strategic Partnership in India, ASX announcement dated 10 April 2025
2. ReNerve Secures Marketing Approval in India, ASX announcement dated 10 August 2026
3. Quarterly Activities Report for the Period Ended 30 September 2026, ASX announcement dated 26 October 2026
4. Annual Report – Financial Year Ended 30 June 2026, ASX announcement dated 28 August 2026
5. ReNerve Secures Marketing Approval in Indonesia, ASX announcement dated 7 July 2026
6. ReNerve completes first cases in Hong Kong and Malaysia, ASX announcement dated 21 September 2026
Note: reference titles have been drawn from public reporting of the relevant announcements and should be checked against the exact titles
and dates on the ASX announcements platform before release.
3 | P a g e
For further information and enquiries, please contact:
Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au
Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au
About ReNerve Limited (ASX:RNV)
ReNerve Limited (ASX:RNV) is an Australian medical device company developing products for peripheral nerve
injury (PNI) repair. Founded by a neurosurgeon and medtech researchers, ReNerve is focused on ready-to-use
solutions designed to support peripheral nerve surgery and improve patient outcomes. The Company’s lead
product is the FDA-cleared NervAlign® Nerve Cuff, complemented by the Empliq® range of human tissue products
for surgical and wound-care applications. ReNerve’s product pipeline includes the NervAlign® Nerve Conduit and
the NervAlign® Nerve Guide Matrix, currently in development. ReNerve products are commercialised in the United
States, New Zealand, Hong Kong, Thailand, Malaysia, Indonesia, the Philippines and India. For more information
visit [www.renerve.com.au].
Share your feedback
Discover